Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Recruiting · NCT06252675 · Registry updated 2026-10-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Recruiting | Phase 2 | 2026-10-01 | NCT06252675 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Adaptive Biotechnologies | 6 |
| Eli Lilly and Company | 370 |
| Genentech, Inc. | 221 |
| University of California, San Francisco | 637 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of California, Davis | Davis | United States | 12 |
| University of California, Los Angeles | Los Angeles | United States | 142 |
| University of California, San Diego | San Diego | United States | 29 |
| University of California, San Francisco | San Francisco | United States | 294 |